




# PHARMACEUTICAL 2021

Anixa Biosciences Inc  
Rank 227 of 402





# PHARMACEUTICAL 2021

Anixa Biosciences Inc  
Rank 227 of 402



The relative strengths and weaknesses of Anixa Biosciences Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Anixa Biosciences Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 61% points. The greatest weakness of Anixa Biosciences Inc is the variable Net Income, reducing the Economic Capital Ratio by 109% points.

The company's Economic Capital Ratio, given in the ranking table, is 77%, being 30% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	9,369
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,189
Liabilities, Non-Current	0
Other Assets	84
Other Compr. Net Income	0
Other Expenses	148
Other Liabilities	0
Other Net Income	34
Other Revenues	0
Property and Equipment	0
Research and Development	4,381
Selling, General and Administrative Expense	5,597

Output Variable	Value in 1000 USD
Assets	9,453
Liabilities	1,189
Expenses	10,126
Revenues	0
Stockholders Equity	8,264
Net Income	-10,092
Comprehensive Net Income	-10,092
Economic Capital Ratio	77%